USOSM Expands Best-in-Class Network of Premier Oral and Maxillofacial Surgeons
IRVING, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM) is pleased to announce new partnerships with three premier oral and maxillofacial surgery (OMS) practices – two in California and one in Pennsylvania. They are Beaudry Oral & Maxillofacial Surgery of Camp Hill, PA; Kern Oral & Facial Surgery & Rejuvenating Beauty of Bakersfield, CA; and Rancho Oral and Maxillofacial Surgery of Murrieta and Hemet, CA.
'We're excited to continue our growth momentum with the addition of three new partner practices and we're honored to announce our newest surgeon partners are Dr. Beaudry, Dr. Esla and Dr. Pulsipher,' said USOSM President and CEO Richard Hall. 'All three doctors have well established reputations for clinical excellence and professional leadership – qualities that we value highly. We look forward to supporting the continued growth of their practices and their commitment to high quality patient care.'
About the new partners:
Located in Camp Hill, PA, Beaudry Oral & Maxillofacial Surgery is led by Robert J. Beaudry, DMD. Dr. Beaudry offers a full scope of OMS procedures, with particular expertise in dental implant surgery, wisdom tooth removal and corrective jaw surgery. Dr. Beaudry earned his DMD from the Washington University School of Dental Medicine with a special award in prosthetic dentistry and completed his OMS training through The Johns Hopkins Hospital in Baltimore, MD.
Dr. Beaudry is a board certified oral and maxillofacial surgeon and a member of the American Association of Oral and Maxillofacial Surgeons. He has more than 30 years of experience treating patients, has presented OMS lectures across the nation, and has served as an advisor for the development of synthetic TMJ joints, OMS instruments and reconstructive plates.
Led by Alan Esla, DDS, MD, Kern Oral & Facial Surgery & Rejuvenating Beauty offers a full scope of OMS, such as dentoalveolar, reconstructive and corrective jaw surgery, as well as a wide variety of rejuvenating beauty services. A board certified oral and maxillofacial surgeon with more than 20 years of experience treating patients, Dr. Esla earned his bachelor's degree from California State University Northridge and his DDS and MD from the UCLA School of Dentistry. In addition, he completed a general surgery internship and an OMS residency through the UCLA Medical Center.
Dr. Esla currently serves as a general anesthesia examiner for the Dental Board of California and is a member of the American Association of Oral and Maxillofacial Surgeons, the California Association of Oral and Maxillofacial Surgeons, the American Dental Association, the California Dental Association and the Kern County Dental Society, where he is a past president.
Rancho Oral and Maxillofacial Surgery has one location in Murrieta, CA, and another location in Hemet, CA. Accredited as an office-based surgery center by the Accreditation Association for Ambulatory Health Care, Rancho Oral and Maxillofacial Surgery is led by Allen Pulsipher, DDS, MD, FACS. Dr. Pulsipher offers a full scope of OMS services, with an emphasis on dental implants, including anterior aesthetic implants, soft tissue reconstruction, bone grafting, bone reconstruction and full-mouth restoration.
Dr. Pulsipher earned his bachelor's degree from Brigham Young University, his DDS from Baylor College of Dentistry, and his MD from UT Southwestern. In addition, he has completed OMS, general surgery, and anesthesia training, and he is a board certified oral and maxillofacial surgeon. Dr. Pulsipher is a fellow of both the American Association of Oral and Maxillofacial Surgeons and the American College of Surgeons, president of Inland Facial Trauma Surgery, and founder and director of the Mount Palomar Study Club.
Headquartered in Irving, Texas, USOSM sets the standard for oral and maxillofacial surgery management. A management services organization spanning 28 states, USOSM has built a best-in-class network of premier oral and maxillofacial surgeon partners. USOSM provides operational, financial and administrative support services to fuel clinical excellence, innovation and wealth-creation. Visit: https://www.usosm.com.
Robin Stevens
469-242-0475
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
30-05-2025
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-05-2025
- Associated Press
U.S. Oral Surgery Management Announces New Partnerships on East and West Coasts
IRVING, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons –has secured new partnerships with Sierra Foothills Oral & Maxillofacial Surgery in the Sacramento area and Shenandoah Oral & Facial Surgery in Virginia. 'We're thrilled to announce our newest partners: Dr. Harris, Dr. Hill, Dr. Christensen and Dr. Quitmeyer,' said USOSM President and CEO Richard Hall. 'All of whom are board-certified oral and maxillofacial surgeons of the highest quality.' Sierra Foothills Oral & Maxillofacial Surgery has four locations in the Sacramento area, including Roseville, Auburn, Folsom and Natomas. The practice has three board-certified oral and maxillofacial surgeons, the highest credential that can be obtained in the specialty, according to the American Board of Oral and Maxillofacial Surgery. They are Brian C. Harris, DDS, MD; Wes L. Hill, DDS, MD; and Brandon Christensen, DMD. The surgeons offer comprehensive OMS treatments. The assisting staff includes registered dental assistants and certified oral surgery assistants, who have had extensive training and experience in oral surgery and anesthesia procedures to ensure the highest levels of patient safety and comfort. The Sierra Foothills Oral & Maxillofacial Surgery care team strives to provide each patient with an exceptional oral health experience that restores balance, comfort and function. Led by Aaron E. Quitmeyer, DDS, Shenandoah Oral & Facial Surgery is located in Harrisonburg in Virginia's Shenandoah Valley region. A board-certified oral and maxillofacial surgeon, Dr. Quitmeyer offers a full scope of OMS procedures. Dr. Quitmeyer earned his bachelor's degree from Macalester College and his DDS from the University of Minnesota School of Dentistry. Afterward, Dr. Quitmeyer earned a commission in the U.S. Navy and completed his residency in Okinawa, Japan. He practiced general dentistry there for two years before being selected into the highly competitive OMS program, where he served as chief resident. Dr. Quitmeyer graduated from the Naval Medical Center Portsmouth and served as the oral and maxillofacial surgeon onboard the aircraft carrier USS Harry S. Truman. Afterward, he became the associate program director of the NCC OMS residency program at the Walter Reed National Military Medical Center, where he taught residents the full range of OMS procedures, prior to going into private practice. Headquartered in Irving, Texas, USOSM sets the standard for oral and maxillofacial surgery management. A management services organization spanning 29 states, USOSM has built a best-in-class network of premier oral and maxillofacial surgeon partners. USOSM provides operational, financial and administrative support services to fuel clinical excellence, innovation and wealth-creation. Visit: Contact: Robin Stevens U.S. Oral Surgery Management 469-242-0475 [email protected]
